PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China.\', \'Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China.\', \'Drug Clinical Trail Institution, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.\', \'Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.\', \'Department of Respiratory Medicine, the Second People\'s Hospital of Fuyang, Fuyang, 236000, China.\', \'Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Hunan Provincial Clinical Research Center for Respiratory Diseases, Changsha, 410000, China.\', \'Intensive Care Unit, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China.\', \'Lu\'an People\'s Hospital Affiliated to Anhui Medical University, Lu\'an, 237005, China.\', \'Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical College, Clinical Research Center for Respiratory Disease (tumor) in Anhui Province, Bengbu, 233004, China.\', \'Department of Respiratory Medicine, Anqing Hospital Affiliated to Anhui Medical University, Anqing, 246000, China.\', \'The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China.\', \'Department of Rheumatology and Immunology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China.\', \'Department of Oncology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China.\', \'Department of Endocrinology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China.\', \'Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China.\', \'Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China. hfmxd@sina.com.\', \'Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China. ustcwhm@ustc.edu.cn.\', \'Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China. xxlahh8@ustc.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s11684-020-0824-3
?:hasPublicationType
?:journal
  • Frontiers of medicine
is ?:pmid of
?:pmid
?:pmid
  • 33687643
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.913
?:rankingScore_hIndex
  • 25
is ?:relation_isRelatedTo_publication of
?:title
  • Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all